Stay updated on Patisiran for hATTR Amyloidosis Clinical Trial
Sign up to get notified when there's something new on the Patisiran for hATTR Amyloidosis Clinical Trial page.

Latest updates to the Patisiran for hATTR Amyloidosis Clinical Trial page
- Check7 days agoChange DetectedThe page now displays the expanded-access study record for patisiran in hereditary transthyretin-mediated amyloidosis, including study details, eligibility criteria, intervention, sponsor, and record dates.SummaryDifference30%

- Check14 days agoChange DetectedThe footer revision number changes from v3.7.2 to v3.8.0.SummaryDifference0.2%

- Check21 days agoChange DetectedA site-wide banner announces the NIH transition from using “Artificial Intelligence” to “Super Intelligence” and links to updates and FAQs.SummaryDifference1%

- Check28 days agoChange DetectedThe footer’s ClinicalTrials.gov revision number changes from v3.7.1 to v3.7.2.SummaryDifference0.2%

- Check35 days agoChange DetectedThe footer’s ClinicalTrials.gov revision identifier changes from v3.7.0 to v3.7.1.SummaryDifference0.2%

- Check48 days agoChange DetectedAccess to the study record is blocked by a 403 Forbidden page, with the error document structure added (doctype, metadata, title). A minimal header/footer remains, and many related links and terms have been removed from the page.SummaryDifference14%

Stay in the know with updates to Patisiran for hATTR Amyloidosis Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Patisiran for hATTR Amyloidosis Clinical Trial page.